Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study
Authors:
- Aristotelis BamiasAristotelis Bamias
- Kimon TzannisKTKimon Tzannis
- Roubini ZakopoulouRZRoubini Zakopoulou
- Minas SakellakisMSMinas Sakellakis
- John DimitriadisJDJohn Dimitriadis
- Alkistis PapatheodoridiAlkistis Papatheodoridi
- Loukianos RallidisLRLoukianos Rallidis
- Panagiotis HalvatsiotisPHPanagiotis Halvatsiotis
- Anna TsiaraATAnna Tsiara
- Maria KaparelouMKMaria Kaparelou
- Efthymios KostourosEKEfthymios Kostouros
- Despina BarbarousiDBDespina Barbarousi
Open Access
- 24 August 2022
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 29 (9) , 6077-6090
Abstract
Arterial thromboembolism has been associated with cancer or its treatment. Unlike venous thromboembolism, the incidence and risk factors have not been extensively studied. Here, we investigated the incidence of arterial thromboembolic events (ATEs) in an institutional series of advanced urinary tract cancer (aUTC) treated with cytotoxic chemotherapy. The ATE definition included peripheral arterial embolism/thrombosis, ischemic stroke and coronary events. A total of 354 aUTC patients were analyzed. Most patients (95.2%) received platinum-based chemotherapy. A total of 12 patients (3.4%) suffered an ATE within a median time of 3.6 months from the start of chemotherapy. The most frequent ATE was ischemic stroke (n = 7). Two ATEs were fatal. The 6-month and 24-month incidence were 2.1% (95% confidence interval [CI]: 0.9–4.1) and 3.6% (95% CI: 1.9–6.2), respectively. Perioperative chemotherapy increased the risk for ATE by 5.55-fold. Tumors other than UTC and pure non-transitional cell carcinoma histology were also independent risk factors. No association with the type of chemotherapy was found. Overall, ATEs occur in 4.6% of aUTC patients treated with chemotherapy and represent a clinically relevant manifestation. Perioperative chemotherapy significantly increases the risk for ATE. The role of prophylaxis in high-risk groups should be prospectively studied.Keywords
This publication has 53 references indexed in Scilit:
- Lung Cancer and Incidence of StrokeStroke, 2011
- Increase in stroke risk in patients with head and neck cancer: a retrospective cohort studyBritish Journal of Cancer, 2011
- Global Variation in the Relative Burden of Stroke and Ischemic Heart DiseaseCirculation, 2011
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II studyAnti-Cancer Drugs, 2007
- The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinomaCancer, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- HIGH RISK OF VASCULAR EVENTS IN PATIENTS WITH UROTHELIAL TRANSITIONAL CELL CARCINOMA TREATED WITH CISPLATIN BASED CHEMOTHERAPYJournal of Urology, 1998
- Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial CancerJournal of Urology, 1997